Callyope

The model is the product and it was built rather than borrowed. The company trained an audio and language foundation model on psychiatric data specifically, rather than fine tuning a general purpose speech system, which is the distinction that separates this from most speech based health products. Every function on the clinician side, from symptom scoring to case summarisation to document generation, runs on that same model.

The team is a research team publishing on the model at speech science venues, and the technical founder's doctorate was on automatic assessment of speech in a neurological disease, so the mechanism claim is backed by primary work rather than asserted in marketing.

Conventional and clearly stated, with candour credited. The company states plainly that the system is designed to support clinicians rather than replace them, and that the clinician remains in full control of diagnosis, treatment planning and care. Output is a symptom score and a set of drafted documents that a clinician reviews.

That is the same restraint credited on the MD-Staff and Genomind records, and it matters more than usual here, because a continuous score presented longitudinally carries an implied authority that a single reading does not. What is not addressed is the escalation question: if the model detects deterioration between appointments and nobody opens the dashboard, no published material describes what happens next or who is accountable for noticing.

Well above the norm for this index and the transparency is in the scientific literature rather than in a marketing page. The company presented two papers at Odyssey 2026, one on learning speaker and health related representations from natural language supervision and one on quantized approximate signal processing as a path toward homomorphic encryption for audio.

Separate published work examines which pretext tasks in speech foundation models transfer to mental health detection and how different model layers encode the relevant features, including segment length and pooling strategy. Crucially that work reports results on the Androids dataset, a public third party benchmark, alongside the company's own data, which makes part of the performance externally checkable.

Held at B because the production model is a different artefact from the research papers: weights are not released, the proprietary psychiatric training data is not characterised, and the headline claim of assessing ten or more symptoms from thirty seconds of speech at over ninety percent accuracy is not tied to any published evaluation. Publishing the evaluation behind that specific number would move this to an A.

The right studies are running and the results are not in yet, which is an unusual and honest position rather than a weak one. A registered trial of voice based biomarkers for monitoring and predicting schizophrenia relapse enrols an estimated 200 participants across six months of repeated voice interviews and completes in October 2026, so it is live at the time of this assessment.

The company states seven clinical studies across more than 1,000 patients and a research partnership with one of Europe's largest psychiatric institutions. Against that, no completed clinical outcome study was located. The published work is detection accuracy in machine learning venues, which establishes that speech signal carries symptom information but not that acting on it changes what happens to patients, and those are different claims.

One item is owed: the chief executive said in late 2023 that a scientific paper on general population results would follow the next year, and that paper was not located in two passes. This is the inverse of the evidence paradox recorded in the medication safety lane, where the vendors running the most rigorous designs got the least favourable results. Here a company is running a proper prospective design and simply has not finished.

The strongest stewardship posture encountered in this index, on two independent grounds. First, the company publishes the commitment this index has spent months asking other vendors for and almost never receiving: patient data is never used to train its models without explicit consent, is never shared with third parties, and is encrypted in transit and at rest.

Secondary use of clinical data for model improvement is the single most requested and least published position in this whole market, and it is stated here in plain terms. Second, and rarer still, the company is doing primary research on privacy preserving computation for its own data type, presenting work at Odyssey 2026 on approximate signal processing as a route toward homomorphic encryption for audio.

Voice is among the most identifying data any health product can hold, since it carries speaker identity independently of what is said, and a company researching how to compute on it without decrypting it is addressing the risk at its root rather than wrapping it in policy. Very few vendors anywhere in this index conduct original privacy research.

Graded against the framework that actually governs the company rather than the American one, following the precedent set on the LGPD scoping call. This is a French company operating under the General Data Protection Regulation, and it states full compliance with it and the use of hosting certified under the French Hebergeur de Donnees de Sante regime for all health data.

That regime is an audited health data specific certification rather than a self declaration, which puts it well ahead of the vendors in this index whose entire published position is the phrase HIPAA compliant. It also answers, for this vendor, the certification question left open against Synapse Medicine. Held at B for a distinction worth drawing carefully: the company states that it uses certified hosting, which places the certification with the hosting provider.

Using a certified host and holding certification yourself are different assurances, and the second covers the vendor's own handling of the data once it arrives. No data processing agreement terms, data protection officer contact or processing register were located.

Among the better positions in the recent run of builds, and notable because it is an audited certification rather than an assertion. The company states that it is certified to ISO 27001 and that data is encrypted in transit and at rest. Very few vendors assessed in this index in the last several lanes publish any external certification at all.

Held at B rather than A because the certification is stated without a certificate number, an issuing body or a declared scope, and scope is where ISO 27001 certifications differ most: a certificate covering a corporate function is not the same as one covering the production platform that processes patient speech. No SOC 2 report, penetration testing statement, trust centre or vulnerability disclosure policy was located.

No FDA involvement and no United States market entry located. On the European side, no medical device certification was located either. The relevant statement of intent is on the record from late 2023, when the chief executive described the plan as freezing a version of the proprietary model and submitting it to health authorities for certification, which is the correct sequence and is stated more clearly than most vendors manage.

So the product currently appears to operate outside device certification while positioned to seek it. The boundary is close: software intended to monitor psychiatric symptoms and inform clinical decisions sits within the medical device definition under the European regulation on medical devices, and the company's own description of providing objective data to inform clinical decisions is close to that line. Recorded as a status to re check rather than as a criticism, since a company saying it will certify later is being straightforward about where it stands.

The published research shows awareness of generalisation, examining transfer across languages and speech tasks explicitly, which is more than most vendors attempt. But no bias testing methodology, subgroup performance, model card or drift monitoring concept was located, and one specific exposure is visible in the company's own trial design. The registered schizophrenia study recruits French speakers only and excludes anyone with a condition that impairs French.

Speech models carry documented accuracy variation across accent, dialect and first language, and this index has recorded that the affected populations overlap with those already underserved. A psychiatric speech model validated in one language and marketed in another needs published cross language performance before a clinician can know whether a falling score reflects deteriorating mental state or an accent the model handles less well. That question is sharper here than for a scribe, because the output is a clinical symptom score rather than a transcript a human immediately checks.

The product does move clinical data: it ingests uploaded medical records for case summarisation, takes smartphone sensor signals covering sleep and activity, and emits structured documents including consultation notes, referral letters and hospitalisation reports. What was not located in two passes is any published integration: no named record system, no interoperability standard, and no partnership with a hospital information system supplier.

Delivered as a patient smartphone application plus a clinician web application, which means documents are produced for a clinician to place into the record rather than written back into it, and that manual step is where adoption of this kind of product usually fails. The integration burden in European hospital systems differs from the American one, so an absence here is less telling than it would be for a United States vendor, but it is still an absence.

A clear and well governed answer to where the data goes, and a different answer from the one Carenostics gives. Health data is processed vendor side, hosted under the French health data hosting certification regime, which fixes it inside a European jurisdiction and inside an audited hosting framework rather than leaving residency to a contract term.

That is the strongest posture available to a vendor that must centralise data, and centralising is unavoidable here, since the model consumes speech from a patient's own phone. Held at B rather than A precisely because the data does move: patients transmit voice recordings from personal devices to vendor infrastructure, which is a materially different exposure from software that runs inside a hospital and never sends anything out. No hosting provider, region detail or architecture description was published.

Nothing published. No pricing, no pricing mechanism, no contracting model and no stated basis of charge, and no reimbursement pathway identified in any market, which matters for a product whose value proposition is continuous monitoring between appointments, a service most health systems have no existing code to pay for.

The visible commercial facts are funding: a seed round of roughly 2.2 million euros co led by 360 Capital and Bpifrance Digital Venture with No Label Ventures participating, plus selection for Google's artificial intelligence for health programme and an Amazon Web Services cohort. That is a small round against a product carrying both a research programme and a clinical trial, which is worth a buyer's attention on supplier continuity grounds.

Deliberately narrow on all three of specialty, language and geography. Specialty is psychiatry, covering depression, bipolar disorder, schizophrenia, anxiety, insomnia and psychosis, with the company's own framing extending to psychiatric, cognitive and motor symptoms of brain disorders more broadly.

Setting is outpatient psychiatric care between appointments, plus hospital use through the institutional partnership, which is a real gap to target: the company's stated problem is that a patient with schizophrenia may see a psychiatrist only every four to six weeks and deterioration in that interval goes unobserved.

Coverage is constrained by language before it is constrained by anything else, since a speech model is only validated in the languages it was tested in, and the registered trial is French only. Expansion is therefore a revalidation problem per language rather than a translation problem.